Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Vasodilator stress" patented technology

Vasodilator stress agents, such as adenosine and dipyridamole, increase flow on the basis of a direct dilation of the coronary microcirculation independent of endothelial function. Because CAD brings about endothelial dysfunction, exercise may appropriately demonstrate this reduced CFR; the vasodilator agents may not.

Transdermal anesthetic and vasodilator composition and methods for topical administration

A composition for topical application comprising a therapeutically effective amount of a topical anesthetic, a safe and effective amount of a pharmaceutically acceptable topical vasodilator and a pharmaceutically acceptable carrier and a method of administering the composition to a mammal are disclosed.
Owner:SAMUELS PAUL J +1

Rapid acting injectable formulations

A rapid acting injectable formulation is provided comprising a therapeutic peptide and a vasodilatory agent. The therapeutic peptide has a molecular weight of greater than about 500 Daltons, and the vasodilatory agent is present in an amount effective to increase the absorption of the therapeutic peptide. A method of increasing absorption of a therapeutic peptide by using such a formulation is also provided.
Owner:PEROSPHERE INC

Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance

InactiveUS6858632B2Potent vasodilating effectSmall and null tolerance effectBiocideOrganic chemistryArylTolerability
Novel derivatives of isosorbide mononitrate and its pharmaceutically acceptable salts, which have vasodilating activity with a reduced effect of tolerance, of the general formula (I) in which A and B independently represent any of the groups—ONO2 and —Z—CO—R, wherein Z is an oxygen atom or sulphur atom and R is an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, or the group in which R1 is hydrogen, or an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, with the proviso that one of A or B is always —ONO2, but never both of them at the same time, when Z is an sulphur atom R is an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, and when Z is an oxygen atom R is the group
Owner:LACER SA

Compositions for protection against superficial vasodilator flush syndrome, and methods of use

Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric traction, serotonin, post-menopause, alcohol, monosodium glutamate, mastocytosis, atopic dermatitis, food-allergy or food intolerance, and mast cell activation syndrome, or against individual symptoms of SVFS, superficial vasodilation, feeling of warmth, itching (pruritus) and hives, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, or chalconoid compounds, with appropriate substitutions of their hydroxyl groups to render them water soluble or in combination with a pshospholipid or cyclodextrin to render them to have higher oral absorption, administered alone or together with an anti-superficial vasodilation dose of one or more of, olive kernel oil, a serotonin inhibitor, a prostaglandin inhibitor, willow bark extract. A composition for treating cardiovascular disease with niacin, but without eliciting the SVFS effects of niacin, has also been invented.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT

Methods of device-assisted drug delivery

InactiveUS20060062836A1Improve efficiencyEfficiency of of resultSheet deliveryBandagesDiagnostic agentWhole body
This invention describes the simultaneous or sequential administration of therapeutic or diagnostic agents using different devices in combination with a chemical formulation that incorporates or uses vasomodulatory chemical agents as part of the drug delivery vehicle. Methods include the addition of various vasodilatory and vasoconstrictive agents to enhance the systemic or localized tissue delivery of therapeutic or diagnostic agents delivered into a body through the use of an apparatus or device.
Owner:BIOCHEMICS

Topical compositions for delaying ejaculation and methods of using the same

InactiveUS20090005319A1Reduce sensitivityDelaying ejaculationDipeptide ingredientsMetabolism disorderPenisDelay ejaculation
A method, composition, and kit for topical application of a composition to a male penis to delay premature ejaculation during intercourse without adversely affecting response in a female partner are disclosed. The method includes applying to the penis a topical composition immediately prior to intercourse. The composition includes an effective amount of a vasodilator agent and a desensitizing agent such as an acetyl dipeptide-1 cetyl ester.
Owner:BARMENSEN LABS

Combination antihypertensive wafer

The present invention relates to a planar-shaped drug preparation that quickly dissolves or decomposes in an aqueous environment, for the application of active ingredient combinations for the treatment of hypertension, wherein the drug preparations contain at least two active ingredients that are suitable for the treatment of hypertension, and wherein the antihypertensive drug is selected from the group that encompasses beta receptor blockers, alpha receptor blockers, calcium antagonists, ACE inhibitors, AT1 antagonists, centrally acting antihypertensive drugs, direct vasodilators, and diuretics. The present invention also relates to the use of active ingredient combinations according to the invention for the production of an oral drug preparation for the treatment of high blood pressure, to a method for the therapeutic treatment of hypertension, and to a method for the production of a planar-shaped drug preparation.
Owner:LTS LOHMANN THERAPIE-SYST AG

Methods and Compositions for Facilitating Arterial Access

ActiveUS20100234828A1Increasing arterial diameterBiocideNitro compound active ingredientsAnesthetic AgentArterial diameter
Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.
Owner:RGT UNIV OF CALIFORNIA

Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans

A method and a device are disclosed for transdermal delivery to an animal or human of biological cargo-laden nanoparticles. The particles may include multimodal optical molecular imaging probes. The particles may be delivered by providing them in a form that can be absorbed through the skin and applying them to the skin of an animal or human. The application may be accomplished using biological cargo-laden nanoparticles in a device attachable to the skin. The device may be attached directly to the skin by a device containing a vasodilating agent or agents, or micro needles, or multi-layer time release material. The biological cargo-laden nanoparticles may comprise drugs, vaccines, bio-pharmaceuticals, imaging contrast agents, multimodal imaging contrast agents, biomolecules, or anti-infectives. The device may include a first plurality of different types of biological cargo-laden nanoparticles located in a corresponding second plurality of separate time release layers.
Owner:BRUKER BIOSPIN

Composition and method for treating and preventing musculoskeletal and connective tissue disorders

The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).
Owner:SELMAN HOUSEIN SOSA GUILLERMO

Application of patchouli alcohol in preparation of endothelium-independent vasodilator

The invention discloses application of patchouli alcohol in preparation of an endothelium-independent vasodilator. The invention further discloses a medicine for treating cardiovascular and cerebrovascular diseases caused by endothelial injury. The medicine is a preparation prepared from patchouli alcohol serving as an active ingredient and pharmaceutically acceptable excipients or auxiliary components. The patchouli alcohol has an endothelium-independent vasodilation effect, and has clinical significances for treating the cardiovascular and cerebrovascular diseases.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

Transdermal Delivery of Selexipag Metabolite

InactiveUS20190099383A1Organic active ingredientsAerosol deliveryPulmonary primary hypertensionDisease
Compositions, devices and methods for the transdermal delivery of drugs that are potent vasorelaxants and inhibitors of human platelet aggregation are disclosed. These drugs bind to the IP receptor on endothelial and platelet cells and they are useful in the treatment of pulmonary arterial hypertension and other diseases where vasoconstriction is an issue. The compositions, methods and devices pertain particularly to the transdermal delivery of the selexipag metabolite ACT 333679.
Owner:SAMOS PHARMA LLC

Compounds and methods for treatment of solid tumors

InactiveUS20090239820A1Organic active ingredientsBiocideInterstitial fluid pressureLysosome
The present invention relates to pharmaceutical compositions containing targetable bioconjugates of hydralazine, a direct vasodilating agent previously shown to decrease tumor blood flow, oxygenation and interstitial fluid pressure in solid tumors. These bioconjugates are hydralazine prodrugs that contain hydralazine conjugated to biocompatible carrier molecules which specifically bind to sites that are expressed on a diverse variety of tumor cell types. These hydralazine prodrugs are preferably conjugated through an acid-labile hydrazone link that is designed to be stable in plasma and release hydralazine through acid-catalyzed hydrolysis in the acidic environment of the target tumor. Because these prodrugs are stable at physiological pH and in plasma, they are devoid of systemic vasoactive activity; however, they are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor where the vasoactive activity of hydralazine is restored. These prodrugs selectively bind to tumor-specific receptors on tumor cells, and are degraded in the acidic tumor cell environment or the acidic lysosomal compartments after being internalized into the cell.
Owner:B& G PARTNERS

Method for preparing pterocarpus indicus ethanol extract used for endothelium-dependent vasodilation agent and applications of method

InactiveCN101530450AProven expansionEffective dosageCardiovascular disorderPlant ingredientsPterocarpus santalinus extractVascular dilatation
The invention relates to a method for preparing pterocarpus santalinus ethanol extract used for endothelium-dependent vasodilator and applications of the extract on the medicine or health products of endothelium-independent vasodilator. The preparation method comprises the steps of extracting the pterocarpus santalinus powders thrice in a back-flow way by 70% of ethanol of 6 times, 5 times and 3 times respectively for 2.5h, 2h and 1.5h, decompressing, concentrating, cooling and drying the extract, and finally obtaining the pterocarpus santalinus extract. Suitable auxiliary material is added into the pterocarpus santalinus extract so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.
Owner:北京富华安德生物医药科技开发有限公司

Method for preparing pterocarpus santalinus water extract used as direct vasodilation agent and applications of method

InactiveCN101530453AProven expansionEffective dosageCardiovascular disorderPlant ingredientsPterocarpus santalinus extractAs Directed
The invention relates to a method for preparing pterocarpus santalinus water extract used as a non-endothelium-dependent vasodilation agent and applications of the extract on the medicines or health products of non-endothelium-dependent vasodilation agent. The preparation method comprises the steps of extracting the pterocarpus santalinus powders thrice by 70% of water circumfluence of 6 times, 5times and 3 times respectively for 2.5h, 2h and 1.5h, decompressing, concentrating, cooling and drying the extract, and finally obtaining the pterocarpus santalinus extract. Suitable auxiliary material is added into the obtained pterocarpus santalinus extract so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.
Owner:北京富华安德生物医药科技开发有限公司

Method for treating noise-induced hearing loss (NIHL)

A method for treating noise-induced hearing loss (NIHL) includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and / or resveratrol.
Owner:RGT UNIV OF MICHIGAN

Methods and compositions for facilitating arterial access

Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.
Owner:RGT UNIV OF CALIFORNIA

Metabolites and oximes with vasodilator and hypotensive activity

Semi-synthetic oximes derived from metabolites extracted from medicinal plants, Senecio nutans and Xenophyllum poposum, the method of preparation thereof and their use as agents with vasodilator and hypotensive effects are provided.
Owner:UNIV DE ANTOFAGASTA

Method for preparing pterocarpus indicus ethanol extract used for direct vasodilation agent and applications of method

InactiveCN101530452AProven expansionEffective dosageCardiovascular disorderPlant ingredientsPterocarpus santalinus extractPharmacy
The invention relates to a method for preparing pterocarpus indicus ethanol extract used for non-endothelium-dependent vasodilation agent and applications of the extract on the medicines or health products of non-endothelium-dependent vasodilation agent. The preparation method comprises the steps of extracting the pterocarpus indicus powders thrice by 70% of ethanol circumfluence of 6 times, 5 times and 3 times respectively for about 2.5h, 2h and 1.5h, distilling and concentrating the extract by decompressing, cooling and drying the extract, and finally obtaining the pterocarpus indicus extract. Suitable auxiliary material is added into the obtained pterocarpus indicus extract in normal pharmacy method so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.
Owner:北京富华安德生物医药科技开发有限公司

Method for extracting hematopoietic stem cells

The invention discloses a method for extracting hematopoietic stem cells, and belongs to the technical field of the extraction of stem cells. The method comprises the steps that a placenta is flushedfrom the exterior with normal saline, 30 mL of an anticoagulant / vasodilator solution is injected at the room temperature; one end of a perfusate needle is inserted into the umbilical artery of the placenta, and the other end of the perfusate needle is inserted into a perfusion container; one end of a reflux liquid needle is inserted into the umbilical vein of the placenta, and the other end of thereflux liquid needle is inserted into the perfusion container to form a perfusion circuit; long-term lavage is carried out for 6 hours with a cell lavage fluid at a flow velocity of 5 drops per minute, and the first-time lavage fluid is collected; lavage is carried out for 30 minutes with the cell lavage fluid at a flow velocity of 5 drops per minute, and the second-time lavage fluid is collected; the first-time lavage fluid and the second-time lavage fluid are mixed to collect the cells, and DMSO is added and mixed with a dextran cell cryoprotectant for cryopreservation. The method for extracting the hematopoietic stem cells has the advantages that the viability is high, and the proportion of CD34+ cells is high.
Owner:福建省海西细胞生物工程有限公司

Yeast extract having vasorelaxing effect

Provided is a vasorelaxant from food that has few side effects and is safe for hypertension patients and healthy persons said to have prehypertension. Also provided are foods and beverages including this composition and foods and beverages such as health foods, functional foods, and health supplements. An extract of yeast is used as an active ingredient. A yeast extract obtained by a simple procedure consisting of hot-water treatment, acid or alkali treatment, and enzyme treatment of yeast was discovered to have a superior vasorelaxing effect as a yeast extract.
Owner:KOHJIN CO LTD

Method for preparing pterocarpus indicus water extract used for endothelium-dependent vasodilation agent and applications of method

InactiveCN101530451AProven expansionEffective dosageCardiovascular disorderPlant ingredientsPterocarpus santalinus extractMedicine
The invention relates to a method for preparing pterocarpus santalinus water extract used for endothelium-dependent vasodilator and applications of the extract on the medicine or health products of endothelium-independent vasodilatior. The preparation method comprises the steps of extracting the pterocarpus santalinus powders thrice in a back-flow way by 70% of water of 6 times, 5 times and 3 times respectively for 2.5h, 2h and 1.5h, decompressing, concentrating, cooling and drying the extract, and finally obtaining the pterocarpus santalinus extract. Suitable auxiliary material is added into the pterocarpus santalinus extract so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.
Owner:北京富华安德生物医药科技开发有限公司

Method for preparing pterocarpus indicus ethanol extract used for direct vasodilation agent and applications of method

InactiveCN101530452BCardiovascular disorderPlant ingredientsPterocarpus santalinus extractPharmacy
The invention relates to a method for preparing pterocarpus indicus ethanol extract used for non-endothelium-dependent vasodilation agent and applications of the extract on the medicines or health products of non-endothelium-dependent vasodilation agent. The preparation method comprises the steps of extracting the pterocarpus indicus powders thrice by 70% of ethanol circumfluence of 6 times, 5 times and 3 times respectively for about 2.5h, 2h and 1.5h, distilling and concentrating the extract by decompressing, cooling and drying the extract, and finally obtaining the pterocarpus indicus extract. Suitable auxiliary material is added into the obtained pterocarpus indicus extract in normal pharmacy method so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.
Owner:北京富华安德生物医药科技开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products